Barclays PLC Intra Cellular Therapies, Inc. Call Options Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2020 Aug 12, 2020	BUY	$14.35 - $26.64 $284,130 - $527,472	19,800 Added 9900.0%	20,000 $513,000
Q4 2019 Feb 10, 2020	SELL	$7.26 - $38.49 $452,298 - $2.4 Million	-62,300 Reduced 99.68%	200 $7,000
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $359,970 - $483,002	33,800 Added 117.77%	62,500 $811,000
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $245,250 - $317,025	22,500 Added 362.9%	28,700 $350,000
Q4 2018 Feb 14, 2019	SELL	$10.36 - $20.96 $175,084 - $354,224	-16,900 Reduced 73.16%	6,200 $70,000
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $374,327 - $505,439	-21,600 Reduced 48.32%	23,100 $408,000
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $327,456 - $550,584	21,600 Added 93.51%	44,700 $941,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $248,787 - $510,510	23,100	23,100 $365,000

379

84.1M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.79B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.